Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial.
Bone metastasis
Radiation therapy
Radiofrequency ablation
Randomized controlled trial
Spine
Vertebrae
Vertebral augmentation
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
23 Nov 2020
23 Nov 2020
Historique:
received:
15
05
2020
accepted:
12
11
2020
entrez:
24
11
2020
pubmed:
25
11
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Spine metastasis is a common occurrence in cancer patients and results in pain, neurologic deficits, decline in performance status, disability, inferior quality of life (QOL), and reduction in ability to receive cancer-directed therapies. Conventional external beam radiation therapy (EBRT) is associated with modest rates of pain relief, high rates of disease recurrence, low response rates for those with radioresistant histologies, and limited improvement in neurologic deficits. The addition of radiofrequency ablation/percutaneous vertebral augmentation (RFA/PVA) to index sites together with EBRT may improve pain response rates and corresponding quality of life. This is a single-center, prospective, randomized, controlled trial in patients with spine metastasis from T5-L5, stratified according to tumor type (radioresistant vs. radiosensitive) in which patients in each stratum will be randomized in a 2:1 ratio to either RFA/PVA and EBRT or EBRT alone. All patients will be treated with EBRT to a dose of 20-30 Gy in 5-10 fractions. The target parameters will be measured and recorded at the baseline clinic visit, and daily at home with collection of weekly measurements at 1, 2, and 3 weeks after treatment, and at 3, 6, 12, and 24 months following treatment with imaging and QOL assessments. The primary objective of this randomized trial is to determine whether RFA/PVA in addition to EBRT improves pain control compared to palliative EBRT alone for patients with spine metastasis, defined as complete or partial pain relief (measured using the Numerical Rating Pain Scale [NRPS]) at 3 months. Secondary objectives include determining whether combined modality treatment improves the rapidity of pain response, duration of pain response, patient reported pain impact, health utility, and overall QOL. ClinicalTrials.gov NCT04375891 . Registered on 5 May 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Spine metastasis is a common occurrence in cancer patients and results in pain, neurologic deficits, decline in performance status, disability, inferior quality of life (QOL), and reduction in ability to receive cancer-directed therapies. Conventional external beam radiation therapy (EBRT) is associated with modest rates of pain relief, high rates of disease recurrence, low response rates for those with radioresistant histologies, and limited improvement in neurologic deficits. The addition of radiofrequency ablation/percutaneous vertebral augmentation (RFA/PVA) to index sites together with EBRT may improve pain response rates and corresponding quality of life.
METHODS/DESIGN
METHODS
This is a single-center, prospective, randomized, controlled trial in patients with spine metastasis from T5-L5, stratified according to tumor type (radioresistant vs. radiosensitive) in which patients in each stratum will be randomized in a 2:1 ratio to either RFA/PVA and EBRT or EBRT alone. All patients will be treated with EBRT to a dose of 20-30 Gy in 5-10 fractions. The target parameters will be measured and recorded at the baseline clinic visit, and daily at home with collection of weekly measurements at 1, 2, and 3 weeks after treatment, and at 3, 6, 12, and 24 months following treatment with imaging and QOL assessments.
DISCUSSION
CONCLUSIONS
The primary objective of this randomized trial is to determine whether RFA/PVA in addition to EBRT improves pain control compared to palliative EBRT alone for patients with spine metastasis, defined as complete or partial pain relief (measured using the Numerical Rating Pain Scale [NRPS]) at 3 months. Secondary objectives include determining whether combined modality treatment improves the rapidity of pain response, duration of pain response, patient reported pain impact, health utility, and overall QOL.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04375891 . Registered on 5 May 2020.
Identifiants
pubmed: 33228756
doi: 10.1186/s13063-020-04895-x
pii: 10.1186/s13063-020-04895-x
pmc: PMC7685662
doi:
Banques de données
ClinicalTrials.gov
['NCT04375891']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
964Références
J Natl Cancer Inst. 2005 Jun 1;97(11):798-804
pubmed: 15928300
Radiology. 2014 Oct;273(1):261-7
pubmed: 24927327
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Cancer Treat Rev. 2001 Jun;27(3):165-76
pubmed: 11417967
Asian Spine J. 2012 Mar;6(1):71-87
pubmed: 22439092
Cochrane Database Syst Rev. 2004;(2):CD004721
pubmed: 15106258
Eur Radiol. 2011 Sep;21(9):2004-10
pubmed: 21533865
Pain. 1999 Nov;83(2):157-62
pubmed: 10534586
Pain Physician. 2014 Jul-Aug;17(4):317-27
pubmed: 25054391
Pain. 1983 Oct;17(2):197-210
pubmed: 6646795
Pract Radiat Oncol. 2017 Jan - Feb;7(1):4-12
pubmed: 27663933
Neuro Oncol. 2013 Oct;15(10):1413-9
pubmed: 24057886
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
J Chronic Dis. 1974 Sep;27(7-8):365-75
pubmed: 4612056
Spine (Phila Pa 1976). 2009 Oct 15;34(22 Suppl):S78-92
pubmed: 19829280